US Brokerage Updates: Salesforce Upgraded by BofA, Adobe Lowered by Wells Fargo

Newsquawk · 2026-10-12

Major Wall Street financial institutions have adjusted their ratings and price targets across several prominent US equities. BofA Securities upgraded Salesforce (CRM) from Underperform to Buy, setting a price target of USD 285, while Wells Fargo downgraded Adobe (ADBE). In other rating changes, Northland lifted C3.ai (AI) from Market Perform to Outperform with a USD 16 price target. Citi raised Allison Transmission (ALSN) and Blackstone Digital Infrastructure Trust (BXDC) to Buy. Wells Fargo shifted Allstate (ALL) to Equal Weight with a USD 236 target. Deutsche Bank moved ASTS SpaceMobile (ASTS) from Hold to Buy, establishing a USD 93 target. JPMorgan elevated Biogen (BIIB) to Overweight with a USD 300 target. Raymond James upgraded BioMarin Pharmaceutical (BMRN) to Strong Buy at USD 109 and Humana (HUM) to Outperform. Keefe, Bruyette & Woods bumped Brown & Brown (BRO) to Outperform at USD 77. Truist Securities pushed First Solar (FSLR) to Buy, and Seaport Global Securities boosted Hexcel (HXL) to Buy with a USD 104 target.

AI 시장 분석

Major Wall Street firms have issued a large number of upgrades and downgrades on key companies. BofA upgraded CRM from Underperform to Buy, while Wells Fargo downgraded ADBE. These changes in analyst ratings are leading to a re-evaluation of individual company valuations, directly impacting investor sentiment. Investors should closely monitor trends in target price (PT) changes by each brokerage.

상승 영향

AI — C3.ai was upgraded to Outperform by Northland with a target price of USD 16, improving investment sentiment in the related sector.
Biotech — Biogen was upgraded to Overweight by JPMorgan (target price USD 300) alongside an upgrade for BioMarin, raising earnings expectations.

하락 영향

Software — ADBE received a rating downgrade from Wells Fargo, causing short-term downward pressure on stock prices and a contraction in investor sentiment.

DYAX 전담 분석

Upgrades in investment ratings by major brokerages reflect expectations of improving fundamentals for those companies and serve as a short-term stock price momentum driver. In particular, target price hikes for stocks within specific sectors such as AI and biotech (e.g., C3.ai USD 16, Biogen USD 300) are stimulating capital inflows.

In a bullish scenario, upgraded stocks will prove earnings improvements and lead index gains, whereas in a bearish scenario, profit-taking sell-offs may emerge if target prices fail to be met. Therefore, earnings releases and the inflow of institutional buying must be closely monitored as key indicators.

AI가 생성한 분석으로 투자 자문이 아닙니다.

DYAX Investor Sentiment

Bullish (Long) 35% · Bearish (Short) 65%

425 participants

Related News

원문 보기 — Newsquawk